Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovatirelin in Spinocerebellar Degeneration
NCT02889302Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rovatirelin in spinocerebellar degeneration (SCD), sponsored by Kissei Pharmaceutical Co., Ltd.. Started Nov 2016; status: completed.
02
Drugs
rovatirelin
03
Conditions
spinocerebellar degeneration (SCD)
Beyond the preview
Go deeper on NCT02889302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889302.